---
title: "Crispr Therapeutics AG (CRSP) Gets a Buy from Piper Sandler"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285198432.md"
description: "Piper Sandler analyst Edward Tenthoff has reiterated a Buy rating on Crispr Therapeutics AG (CRSP) with a price target of $110.00. Tenthoff, who focuses on the Healthcare sector, has an average return of 7.4% and a 41.31% success rate on his stock recommendations. Additionally, Needham's Gil Blum also issued a Buy rating for Crispr Therapeutics AG today, while RBC Capital maintained a Hold rating yesterday."
datetime: "2026-05-05T11:35:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285198432.md)
  - [en](https://longbridge.com/en/news/285198432.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285198432.md)
---

# Crispr Therapeutics AG (CRSP) Gets a Buy from Piper Sandler

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Crispr Therapeutics AG, with a price target of $110.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Tenthoff covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Moderna, and Alnylam Pharma. According to TipRanks, Tenthoff has an average return of 7.4% and a 41.31% success rate on recommended stocks.

In addition to Piper Sandler, Crispr Therapeutics AG also received a Buy from Needham’s Gil Blum in a report issued today. However, yesterday, RBC Capital maintained a Hold rating on Crispr Therapeutics AG (NASDAQ: CRSP).

### Related Stocks

- [CRSP.US](https://longbridge.com/en/quote/CRSP.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [WDNA.US](https://longbridge.com/en/quote/WDNA.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [ARKK.US](https://longbridge.com/en/quote/ARKK.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IDNA.US](https://longbridge.com/en/quote/IDNA.US.md)
- [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md)
- [KPTI.US](https://longbridge.com/en/quote/KPTI.US.md)
- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)
- [RY.US](https://longbridge.com/en/quote/RY.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)
- [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md)